English
日本語
한국어
简体中文
繁體中文
Italiano
español
Deutsch
Русский
With the help of a university professor and a psychiatrist, I created a project to discuss the function of pharmaceuticals in modifying synaptic plasticity linked with aging diseases, particularly Alzheimer's disease, and I presented it to the health comm
忙しい方、やり方が不明な方は
代行リクエストを依頼する
レッスンの詳細
This presentation was developed in English.
The onset of neurodegenerative disorders has increased exponentially with age, suggesting that the brain is particularly susceptible to the aging process. Alzheimer's disease starts with an asymptomatic stage and biomarker evidence of the condition and progresses by expressing mild cognitive and/or neurobehavioral abnormalities until it reaches the state of dementia.
The hippocampus, essential in the regulation of learning and memory, is the brain structure most affected by Alzheimer's disease. It exhibits incredible structural and functional plasticity in response to environmental changes, making it an important target for research.
Aducanumab, a kind of human monoclonal antibody, has been approved by the U.S. Food and Drug Administration to treat Alzheimer's patients. It will be available in the US from June 7, 2021.
Aducanumab has emerged as the most promising treatment for AD during the past ten years. Other non-pharmacological therapies, stem cell therapy and hyperbaric oxygen therapy are two potential candidates to help prevent and/or treat Alzheimer's.
Early diagnosis of AD allows access to treatment options that do not cure the disease but reduce cognitive and functional decline at an early stage. It also opens new horizons for people to change their lifestyle to prevent aging related diseases and stay healthy longer.
The hippocampus, essential in the regulation of learning and memory, is the brain structure most affected by Alzheimer's disease. It exhibits incredible structural and functional plasticity in response to environmental changes, making it an important target for research.
Aducanumab, a kind of human monoclonal antibody, has been approved by the U.S. Food and Drug Administration to treat Alzheimer's patients. It will be available in the US from June 7, 2021.
Aducanumab has emerged as the most promising treatment for AD during the past ten years. Other non-pharmacological therapies, stem cell therapy and hyperbaric oxygen therapy are two potential candidates to help prevent and/or treat Alzheimer's.
Early diagnosis of AD allows access to treatment options that do not cure the disease but reduce cognitive and functional decline at an early stage. It also opens new horizons for people to change their lifestyle to prevent aging related diseases and stay healthy longer.
この講師の キャンセルポリシー
リクエスト確定前
- いつでも無料キャンセル可能。
リクエスト確定後
- レッスン開始時刻の 24時間以内→ ご利用ポイントの 50% を頂いております。
- レッスンに現れなかった場合→ ご利用ポイントの 100% を頂いております。
この講師のレッスン
すべて
-
-
PORTUGUESE STEP BY STEP (SHORT VERSION)
予定がたくさん入っていて忙しいでしょうか？日々のことを少し話すだけでもタメになりますよ。こちらは15分の短いレッスンです！15分 700P -
-
ENGLISH STEP BY STEP (SHORT VERSION)
予定がたくさん入っていて忙しいでしょうか？日々のことを少し話すだけでもタメになりますよ。こちらは15分の短いレッスンです！15分 600P -
ENGLISH STEP BY STEP
This is a 30 minute break from your daily routine to practice your English speaking skills. Let's talk!30分 1,200P -
Professional English Writing and Communication
"Professional English Writing and Communication" is a class designed to help non-native English speakers improve their ability to write effective and clear emails and paperwork in English.30分 1,200P
